GlassScriptPhysician profile
Katja Felsinger
NPI 1609839505
$3,798.08
in general payments reported to CMS, 2019-2025
28 companies · $673 in 2025
The $673 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $379 · 2022: $965 · 2023: $1,230 · 2024: $550 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $621.64 | 2021-2025 | Mounjaro, Jardiance, Lyumjev |
| Novo Nordisk INC | $573.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $358.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.49 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Sanofi-Aventis U.S. LLC | $295.67 | 2021-2023 | |
| Mannkind Corporation | $223.09 | 2022-2023 | Afrezza |
| Amgen INC. | $213.64 | 2022-2025 | Repatha, Repatha, Evenity |
| Xeris Pharmaceuticals, INC. | $203.04 | 2021-2025 | Gvoke Hypopen |
| Insulet Corporation | $148.32 | 2021-2024 | Omnipod |
| Dexcom, INC. | $125.97 | 2021-2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $80.36 | 2023-2025 | Unithroid |
| Esperion Therapeutics, INC. | $69.72 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $66.40 | 2025 | Korlym |
| Abbott Laboratories | $63.25 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $56.81 | 2021-2024 | Minimed 780g |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $50.23 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $48.71 | 2022-2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $45.61 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.59 | 2021-2022 | |
| Cequr Corporation | $35.69 | 2025 | Cequr Simplicity |
| Glaxosmithkline, LLC. | $35.04 | 2025 | Shingrix, Arexvy |
| Neurocrine Biosciences, INC. | $23.58 | 2025 | |
| Sequel Med Tech, LLC | $23.20 | 2025 | Twiist |
| Ibsa Pharma INC. | $21.35 | 2023 | Tirosint, Licart |
| Madrigal Pharmaceuticals | $18.46 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $16.80 | 2023 | |
| Averitas Pharma INC. | $16.45 | 2024 | Qutenza |
| Antares Pharma, INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katja Felsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.